We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients.
- Authors
Facchin, Sonia; Buda, Andrea; Cardin, Romilda; Agbariah, Nada; Zingone, Fabiana; De Bona, Manuela; Zaetta, Debora; Bertani, Lorenzo; Ghisa, Matteo; Barberio, Brigida; Savarino, Edoardo Vincenzo
- Abstract
Anti-drug antibodies can interfere with the activity of anti-tumor necrosis factor (TNF) agents by increasing drug clearance via direct neutralization. The presence of anti-drug antibodies is clinically relevant when trough drug concentrations are undetectable or sub-therapeutic. However, traditional immunoassay is not easily and rapidly accessible, making the translation of the results into treatment adjustment difficult. The availability of a point-of-care (POC) test for therapeutic drug monitoring (TDM) might represent an important step forward for improving the management of inflammatory bowel disease (IBD) patients in clinical practice. In this pilot study, we compared the results obtained with POC tests with those obtained by enzyme-linked immunosorbent assay (ELISA) in a group of IBD patients treated with Infliximab (IFX). We showed that POC test can reliably detect presence of antibody-to-IFX with 100% of specificity and 76% sensitivity, in strong agreement with the ELISA test (k -coefficient = 0.84).
- Subjects
DRUG monitoring; PATIENT monitoring; INFLAMMATORY bowel diseases; ENZYME-linked immunosorbent assay; IMMUNOGLOBULINS
- Publication
Therapeutic Advances in Gastroenterology, 2021, Vol 14, p1
- ISSN
1756-283X
- Publication type
Case Study
- DOI
10.1177/1756284821999902